Scientist.com Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition Globally
Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research.
Through the new COMPLI™ feature, Scientist.com provides a simple, efficient and effective way of increasing the visibility and accessibility of biobanks’ human biological samples collections, which support new medical research. COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks to more easily connect with researchers in the pharmaceutical and biotech industries and academia.
“Our goal is to put researchers who require human biological samples in touch with biobanks that have those samples in a platform that promotes compliance, efficiency, transparency, control and respect for the original donor,” stated Matt McLoughlin, Senior Director of Compliance at Scientist.com.
The UKCRC TDCC supports the work of biobanks by improving visibility of their human tissue samples for research purposes. The Centre helps biobanks maintain sustainability by providing access to consistent revenue streams that support the ongoing upkeep and maintenance necessary to keep biobanks compliant with ethical standards and governmental regulations.
“The aim is to enable biobanks throughout the UK to easily connect and work with Scientist.com’s large international customer base,” stated Philip Quinlan, Director of the UKCRC Tissue Directory and Coordination Centre. “The initiative should save time, reduce costs and improve compliance oversight.”
About Scientist.com
Scientist.com is the world’s leading scientific services marketplace. The marketplace simplifies research sourcing, saves time and money and provides access to innovative tools and technologies, while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US National Institutes of Health (NIH). Visit scientist.com to learn more.
Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.
About the UKCRC TDCC
The UKCRC Tissue Directory and Coordinator Centre was set up to support the work of biobanks by improving access to their human samples for research purposes. This was a direct response to the UKCRC Funders’ Vision for Human Tissue Resources, which sought for the maximisation of human tissue samples and resources for medical research. The UKCRC funders that have funded the Centre include Medical Research Council, Cancer Research UK, National Institute for Health Research, Wellcome Trust, British Heart Foundation, Chief Scientist Office (Scottish Government Health Directorates), Health and Care Research Wales and the HSC Research and Development Division, Public Health Agency for Northern Ireland. For more information about the Centre, please see the website: www.biobankinguk.org. To access the Tissue Directory, please see the website: https://directory.biobankinguk.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018005218/en/
Contact information
Scientist.com
Sean Preci
Director of Communications
+1-858-455-1300
ext. 401
marketing@scientist.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reintroducing Global Blue to Retailers and Shoppers Worldwide19.3.2024 13:19:00 CET | Press release
Taking shopping further through the power of experience Over 40 years ago, Global Blue pioneered the concept of Tax Free Shopping, changing the retail landscape and empowering international shoppers worldwide. Since then, its journey has evolved, now encompassing three families of solutions: Tax Free Shopping, Payments, and Post-Purchase Solutions. Within these industries, Global Blue consistently leverages its integrated software and data to bring value at every step of the journey and take shopping further. Driven by this commitment, Global Blue teams create engaging experiences that foster connections between consumers and brands while simplifying processes, to ensure every customer journey is seamless and intuitive. Through these efforts, Global Blue enables its clients to seize business opportunities, enhance customer loyalty, boost sales, and optimize operations and costs. “At Global Blue, we firmly believe that improving the shopping journey drives performance. This renewed focu
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation19.3.2024 13:00:00 CET | Press release
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK. Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024. “Considering the rapid progression of
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up19.3.2024 13:00:00 CET | Press release
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/ The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire) The publication is available here: https://www.sciencedirect.com/science/article/pii/S1094715924000552 The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space19.3.2024 13:00:00 CET | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/ HummingSat I-8 Inmarsat (Photo: Business Wire) SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from l
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 12:04:00 CET | Press release
AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee